sever
acut
respiratori
syndrom
sar
newli
identifi
infecti
diseas
caus
novel
zoonot
coronaviru
sarscov
unknown
anim
reservoir
risk
sar
reemerg
human
remain
high
due
larg
anim
reservoir
sarscovlik
coronaviru
genom
instabl
rna
coronavirus
epidem
affect
patient
countri
mortal
sar
infect
transmit
air
droplet
clinic
laboratori
manifest
includ
fever
chill
rigor
myalgia
malais
diarrhea
cough
dyspnoea
pneumonia
lymphopenia
neutrophilia
thrombocytopenia
elev
serum
lactat
dehydrogenas
alanin
aminotransferas
creatin
kinas
activ
health
care
worker
highrisk
group
advanc
age
strongli
associ
diseas
sever
treatment
empir
licens
sar
vaccin
human
far
howev
presenc
longliv
neutral
antibodi
memori
tand
blymphocyt
convalesc
sar
patient
rais
hope
activ
immun
furthermor
result
preclin
sar
vaccin
express
spike
protein
elicit
neutral
antibodi
cellular
respons
protect
mous
nonhuman
primat
model
encourag
littl
known
earli
event
viral
clearanc
onset
innat
inflammatori
respons
sar
infect
regul
innat
immun
respons
associ
develop
adapt
immun
diseas
sever
sar
infect
notabl
sarscov
evolv
evas
strategi
suppress
antivir
type
interferon
respons
infect
cell
addit
inflammatori
respons
character
upregul
proinflammatori
cytokineschemokin
tissu
serum
massiv
infiltr
inflammatori
cell
macrophag
infect
tissu
due
lack
anim
model
mimic
clinic
manifest
human
sar
infect
mechanist
studi
vaccin
evalu
develop
safe
prophylact
sar
vaccin
human
use
remain
huge
challeng
chapter
written
summar
highlight
latest
clinic
serolog
immunolog
paramet
relev
pathogenesi
protect
immun
sar
infect
human
sarscov
largest
rna
viru
classifi
group
coronaviru
famili
nichol
et
al
marra
et
al
stadler
et
al
virion
roughli
nm
diamet
envelop
positivestrand
rna
viru
contain
lipid
bilay
surround
helic
nucleocapsid
structur
protect
genom
genom
size
kb
length
encod
open
read
frame
orf
major
orf
encod
four
structur
protein
spike
protein
kda
envelop
e
protein
kda
membran
protein
kda
nucleocapsid
n
protein
kda
replicas
protein
encod
twothird
sarscov
genom
essenti
polyprotein
process
replicas
complex
format
effici
viru
replic
protein
orf
orf
orf
orf
orf
import
apoptosi
antagon
type
interferon
respons
infect
cell
chan
et
al
law
et
al
tan
et
al
freundt
et
al
n
protein
essenti
format
helic
nucleocapsid
virion
assembl
recent
n
protein
found
modul
tgfb
signal
block
apoptosi
sarscovinfect
host
cell
import
implic
tissu
fibrosi
zhao
et
al
entri
sarscov
host
target
cell
mediat
surfac
spike
protein
bind
fuse
host
cell
mechan
membran
fusion
sarscov
similar
class
fusion
protein
hiv
influenza
hemagglutinin
review
kielian
rey
ntermin
half
protein
contain
receptorbind
domain
rbd
ctermin
half
membraneanchor
subunit
encod
put
fusion
peptid
two
heptad
repeat
region
liu
et
al
bosch
et
al
entri
sarscov
host
target
cell
involv
receptor
bind
conform
chang
protein
follow
cathepsin
lmediat
proteolysi
within
endosom
simmon
et
al
tripet
et
al
bosch
et
al
hofmann
pohlmann
function
receptor
spike
protein
sarscov
metallopeptidas
angiotensinconvert
enzym
li
et
al
express
human
lung
alveolar
epitheli
cell
type
type
ii
pneumocyt
enterocyt
small
intestin
brush
border
proxim
tubular
cell
kidney
endotheli
cell
arteri
vein
arteri
smooth
muscl
cell
sever
organ
ham
et
al
sarscov
infect
cell
depend
activ
proteolyt
enzym
cathepsin
l
phsensit
simmon
et
al
huang
et
al
henc
tissu
tropism
viral
replic
sarscov
organ
could
explain
distribut
receptor
cathepsin
l
activ
tissu
addit
sar
infect
could
enhanc
ctype
lectin
dcsign
lsign
yang
et
al
jeffer
et
al
interest
note
anoth
newli
identifi
human
coronaviru
caus
minor
cold
also
use
receptor
infect
independ
cathepsin
l
hofmann
et
al
huang
et
al
protect
function
acut
lung
injuri
regul
balanc
angiotensin
angiotensinconvert
enzym
ace
reninangiotensin
pathway
tissu
injuri
caus
angiotensin
ii
could
neg
regul
anim
model
acut
lung
injuri
acut
lung
failur
could
induc
inject
sar
protein
downregul
moreov
effect
could
attenu
block
reninangiotensin
pathway
although
huge
global
public
health
initi
success
contain
sar
outbreak
risk
reemerg
sar
human
remain
high
due
larg
number
anim
reservoir
harbor
sarscovlik
coronaviru
phylogenet
studi
shown
sarscov
zoonot
viru
cross
speci
barrier
evolv
palm
civet
human
observ
sarscov
becam
increasingli
virul
follow
humantohuman
transmiss
review
zhao
howev
failur
isol
sarscov
wild
farm
civet
nonepidem
area
argu
civet
natur
reservoir
viru
shi
hu
recent
sequenc
analysi
sarscovlik
virus
wild
anim
suggest
wild
bat
natur
reservoir
sarscov
lau
et
al
li
et
al
case
would
difficult
control
spread
viru
human
popul
bat
asymptomat
carrier
mani
human
pathogen
hendra
nipha
paramyxovirus
murray
et
al
chua
et
al
given
highli
infecti
properti
complex
public
health
impact
sar
infect
urgent
need
develop
effect
treatment
prophylact
vaccin
control
prevent
futur
sar
outbreak
far
consensu
regard
whether
treatment
especi
use
steroid
convalesc
plasma
therapi
could
benefit
sar
patient
stockman
et
al
moreov
role
play
host
immun
sarscov
viral
clearanc
tissu
damag
diseas
progress
clear
high
initi
viral
load
shown
independ
associ
sever
diseas
may
influenc
host
immun
respons
chu
et
al
howev
recent
studi
suggest
type
ifn
play
key
role
switch
innat
adapt
immun
acut
phase
sar
inde
patient
poor
outcom
show
type
ifnmedi
immunopatholog
event
defici
adapt
immun
respons
cameron
et
al
sever
studi
shown
recov
sar
patient
higher
sustain
antibodi
respons
compar
observ
fatal
case
temperton
et
al
ho
et
al
taken
togeth
suggest
antibodi
respons
like
play
import
role
determin
ultim
diseas
outcom
sar
infect
sever
form
possibl
vaccin
attenu
inactiv
sarscov
dna
viral
vectorbas
vaccin
evalu
number
anim
model
includ
nonhuman
primat
robert
et
al
neutral
antibodi
protein
major
compon
protect
immun
yang
et
al
zhu
et
al
howev
anim
model
includ
nonhuman
primat
lack
sever
clinic
featur
observ
human
hogan
henc
difficult
evalu
whether
vaccin
prevent
diseas
human
progress
complic
concern
safeti
coronaviru
vaccin
inde
immunemedi
enhanc
patholog
report
anim
coronaviru
infect
review
perlman
dandekar
well
anim
vaccin
modifi
vaccin
viru
encod
sarscov
protein
weingartl
et
al
addit
variant
sarscov
resist
antibodi
neutral
infect
enhanc
antibodi
yang
et
al
kam
et
al
inflammatori
respons
strongli
implic
pathogenesi
sar
full
understand
mechan
protect
immun
sarscov
human
critic
develop
safe
prophylact
vaccin
use
human
host
respons
viral
infect
includ
immun
activ
program
cell
death
resist
mani
viral
infect
predominantli
mediat
adapt
immun
compris
humor
cellmedi
immun
review
zinkernagel
hengartn
antivir
effect
humor
immun
mediat
gener
neutral
antibodi
capabl
block
viru
entryinfect
target
cell
effector
compon
cellmedi
immun
cell
mediat
antivir
effect
secret
cytokineseffector
molecul
kill
virusinfect
target
cell
recent
increas
evid
develop
adapt
immun
govern
initi
interact
invad
microorgan
innat
immun
system
sarscov
viru
evolv
way
evad
innat
antivir
type
interferon
respons
host
cell
order
prolong
viral
replic
surviv
review
frieman
baric
recent
studi
also
suggest
dysregul
type
ii
interferon
respons
may
culmin
failur
switch
hyperinn
immun
protect
adapt
immun
respons
sar
patient
poor
outcom
cameron
et
al
proteom
analysi
plasma
sar
patient
show
activ
innat
immun
respons
sarscov
includ
increas
acut
phase
protein
serum
amyloid
mbl
chen
et
al
mbl
could
bind
sarscov
inhibit
viru
infect
vitro
block
carbohydraterecognit
domain
protein
ip
et
al
moreov
low
mbl
serum
level
haplotyp
associ
mbl
defici
observ
sar
patient
reduct
nk
cell
nk
cell
detect
cours
sar
infect
reduct
associ
diseas
sever
anonym
et
al
howev
signific
chang
sar
pathogenesi
clear
mous
model
sar
infect
nk
nkt
cell
requir
viral
clearanc
beig
mice
glass
et
al
drastic
elev
cytokin
chemokin
known
cytokin
storm
tissu
serum
classic
featur
acut
sar
infect
ng
et
al
wong
et
al
zhang
et
al
cheung
et
al
law
et
al
huang
et
al
tseng
et
al
li
et
al
although
consider
variat
literatur
regard
stage
sampl
collect
method
measur
gener
pattern
first
two
week
ill
onset
level
ifng
markedli
upregul
subsequ
reduct
level
cytokin
associ
recoveri
sar
pneumonia
cytokin
predominantli
proinflammatori
cytokin
repres
mainli
innat
immun
respons
monocytesmacrophag
nk
cell
predict
valu
cytokin
diseas
outcom
still
limit
strongli
associ
radiograph
score
increas
cytokin
observ
patient
fatal
outcom
chien
et
al
li
et
al
presenc
immunosuppress
molecul
tgfb
prostaglandin
e
pge
serum
sar
patient
may
provid
altern
explan
prolong
sever
clinic
outcom
huang
et
al
tseng
et
al
li
et
al
furthermor
dysregul
type
ii
interferon
respons
associ
defect
adapt
immun
sever
diseas
outcom
sar
patient
cameron
et
al
cellular
sourc
proinflammatori
cytokineschemokin
identifi
immunocytochem
method
valid
vitro
infect
model
detect
infect
pneumocyt
alveolar
macrophag
infect
lung
immunohistochem
method
jiang
et
al
vitro
condit
sarscov
infect
could
induc
monocytesmacrophag
dendrit
cell
lung
epitheli
cell
produc
cheung
et
al
law
et
al
yen
et
al
among
primari
cell
test
type
ii
pneumocyt
could
support
sarscov
replic
releas
viral
particl
vitro
mossel
et
al
infect
purifi
monocyt
monocytederiv
macrophagesdendrit
cell
peripher
blood
mononuclear
cell
pbmc
sarscov
abort
without
product
matur
viral
particl
although
product
chemokin
impair
yilla
et
al
cheung
et
al
role
cytokin
storm
pathogenesi
sar
similar
human
infect
complex
circular
caus
consequ
relationship
cytokin
make
interpret
difficult
attempt
made
elucid
mechan
vitro
vivo
model
use
polar
lung
epitheli
cell
line
supernat
apic
basolater
domain
infect
epitheli
cell
potent
suppress
phagocyt
function
macrophag
matur
dendrit
cell
tcell
prime
dendrit
cell
yoshikawa
et
al
moreov
inhibit
caus
sarsinfect
epitheli
cell
yoshikawa
et
al
recent
oxid
phospholipid
oxpc
result
sever
inflamm
detect
infect
lung
sampl
patient
fatal
sar
infect
oxid
phospholipid
shown
stimul
product
lung
macrophag
via
pathway
vitro
sheahan
et
al
anim
model
acut
lung
injuri
furthermor
stimul
occur
independ
adaptor
protein
classic
pathway
trigger
lipopolysaccharid
lp
imai
et
al
howev
separ
studi
use
recombin
mouseadapt
sarscov
mice
defici
defect
inflammatori
cell
recruit
suscept
lethal
sarscov
infect
sheahan
et
al
compar
wildtyp
mice
mice
enhanc
pulmonari
patholog
die
day
postinfect
patholog
associ
increas
viral
load
reduct
proinflammatori
cytokin
mononuclear
infiltr
infect
lung
data
suggest
innat
inflammatori
respons
mediat
import
protect
immun
lethal
mouseadapt
sar
infect
excess
inflammatori
cytokin
implic
sever
lung
diseas
sar
infect
import
pathogen
protect
role
proinflammatori
cytokin
chemokin
diseas
progress
need
clarifi
futur
treatment
strategi
inhibit
antivir
type
interferon
ifn
characterist
sar
infect
well
group
coronavirus
mous
hepat
viru
review
frieman
baric
found
product
type
ifn
impair
cell
infect
sarscov
pretreat
cell
ifn
prevent
growth
sarscov
spiegel
et
al
cinatl
et
al
suggest
viru
evolv
strategi
overcom
antivir
ifn
respons
infect
host
cell
type
ifn
rare
detect
acut
sar
patient
sarscov
sensit
antivir
effect
pegyl
ifna
cynomolgu
monkey
model
haagman
et
al
data
vitro
experi
show
suppress
type
ifn
respons
sarscov
infect
cell
due
inactiv
interferon
regulatori
factor
latent
cytoplasm
transcript
factor
regul
ifn
transcript
spiegel
et
al
accessori
protein
sarscov
also
function
potent
ifn
antagonist
via
variou
mechan
n
protein
inhibit
interferon
synthesi
wherea
orf
orf
protein
inhibit
ifn
synthesi
signal
orf
protein
also
inhibit
nuclear
transloc
kopeckybromberg
et
al
recent
orf
shown
shuttl
protein
inhibit
induct
type
ifn
induc
retino
acidinduc
gene
mitochondri
signal
protein
freundt
et
al
moreov
protein
inhibit
type
ifn
product
imped
format
complex
siu
et
al
addit
protein
sarscov
could
suppress
host
ifnb
gene
express
promot
host
mrna
degrad
inhibit
translat
narayanan
et
al
papainlik
proteas
plpro
polyprotein
sarscov
replicas
protein
inhibit
phosphoryl
nuclear
transloc
therebi
disrupt
activ
type
ifn
respons
either
tolllik
receptor
retino
acidinduc
gene
imelanoma
differentiationassoci
gene
pathway
inhibit
ifn
respons
independ
proteas
activ
plpro
devaraj
et
al
besid
sarscov
infect
cell
activ
pkr
perk
result
sustain
phosphoryl
howev
viral
replic
viralinduc
apoptosi
unaffect
krahl
et
al
lymphopenia
common
hematolog
featur
acut
sar
infect
acut
viral
infect
measl
ebola
respiratori
syncyti
viru
schneiderschauli
et
al
formenti
et
al
openshaw
et
al
lymphopenia
observ
sar
patient
differ
studi
reduc
thelper
tcytotoxicsuppressor
cell
count
earli
phase
ill
reach
lowest
valu
day
diseas
onset
fever
restor
gradual
recoveri
phase
wong
et
al
lam
et
al
et
al
low
lymphocyt
count
present
associ
advers
outcom
blymphocyt
count
ratio
thelper
tcytotoxicsuppressor
lymphocyt
remain
normal
stabl
lymphopenia
result
enhanc
cell
death
acut
sar
infect
attribut
activ
cytoplasm
caspas
lymphocyt
chen
et
al
transfect
sar
e
protein
jurkat
cell
could
also
induc
tcell
apoptosi
inactiv
antiapoptot
protein
bclxl
yang
et
al
howev
littl
known
whether
apoptosi
bystand
uninfect
cell
present
acut
sar
infect
littl
data
avail
regard
kinet
correl
sarsspecif
tcell
respons
viral
clearanc
diseas
sever
acut
phase
primari
sar
infect
inform
antigenspecif
tcell
respons
human
retrospect
studi
use
pbmc
sampl
convalesc
sar
patient
zhou
et
al
peng
et
al
peng
et
al
yang
et
al
yang
et
al
poccia
et
al
li
et
al
howev
antigenspecif
respons
convalesc
sampl
provid
inform
memori
respons
lymphocyt
primari
sar
infect
import
gener
design
prophylact
sar
vaccin
recent
advanc
provid
sensit
techniqu
detect
enumer
low
frequenc
antigenspecif
cell
elispot
assay
identifi
surfac
matur
function
phenotyp
multiparamet
flow
cytometri
singl
cell
level
use
matrix
overlap
peptid
span
entir
sarscov
proteom
ifng
elispot
assay
shown
convalesc
sar
patient
endem
area
sar
outbreak
retain
memori
cell
sarscov
protein
peripher
blood
one
year
sar
infect
li
et
al
memori
respons
polyclon
sarsspecif
tcell
respons
direct
differ
sarscov
protein
multipl
epitop
fig
despit
larg
genom
size
sarscov
proteom
fact
strong
associ
memori
respons
neutral
antibodi
protein
recov
sar
patient
howev
overal
sarsspecif
respons
predomin
term
frequenc
magnitud
respons
term
qualiti
cell
polyfunct
statu
sarsspecif
cell
produc
mainli
one
cytokin
tend
central
memori
phenotyp
sarsspecif
respons
ifng
posit
signific
proport
respond
cell
could
also
produc
tnfa
degranul
base
upon
mobil
cell
membran
observ
mildmoder
sever
group
show
frequenc
sarsspecif
memori
produc
ifng
tnfa
significantli
higher
sever
group
mildmoder
group
influenc
preexist
crossreact
cell
human
coronavirus
outcom
sar
infect
unlik
publish
human
sar
epitop
share
amino
acid
sequenc
homolog
known
human
coronavirus
data
independ
studi
also
show
sarsspecif
lymphocyt
e
n
protein
detect
convalesc
sar
sampl
one
four
year
postinfect
use
overlap
peptid
individu
structur
protein
rather
genomewid
approach
peng
et
al
peng
et
al
yang
et
al
yang
et
al
respons
detect
protein
ifng
posit
moreov
protein
respons
predominantli
yang
et
al
librati
et
al
nspecif
cell
could
detect
two
year
postinfect
absenc
antigen
stimul
peng
et
al
b
absenc
antigen
reexposur
memori
cell
specif
sarscov
declin
could
detect
small
proport
convalesc
patient
fan
et
al
use
panel
tcrspecif
antibodi
effectormemori
cell
found
convalesc
sar
patient
poccia
et
al
cell
associ
higher
antisar
igg
level
stimul
cell
display
ifngdepend
antisarscov
activ
abl
kill
sarscov
infect
target
cell
addit
use
predict
algorithm
identifi
put
cytotox
tlymphocyt
ctl
epitop
sspecif
ctl
convalesc
sar
patient
show
differenti
effector
phenotyp
character
separ
studi
ctl
epitop
identifi
could
use
induc
ctl
respons
transgen
mice
dna
immun
zhou
et
al
associ
specif
hla
allel
suscept
sar
infect
diseas
sever
propos
sever
studi
lin
et
al
ng
et
al
howev
due
divers
polymorph
hla
allel
small
number
sampl
test
result
inconclus
antibodi
sarscov
present
patient
primari
sar
infect
use
immunofluoresc
assay
elisa
n
protein
serum
igg
could
detect
earli
four
day
ill
onset
serum
igg
igm
iga
respons
sarscov
present
around
time
patient
seroconvert
day
ill
onset
hsueh
et
al
followup
studi
convalesc
sar
patient
sarsspecif
igg
neutral
antibodi
peak
month
diminish
thereaft
liu
et
al
cao
et
al
igg
neutral
antibodi
detect
convalesc
patient
respect
month
signific
differ
kinet
specif
antibodi
regard
diseas
sever
use
steroid
type
number
coexist
condit
larg
studi
sar
patient
antibodi
abl
neutral
pseudotyp
virus
bear
protein
four
differ
sarscov
strain
suggest
antibodi
crossreact
nie
et
al
among
structur
protein
protein
elicit
neutral
antibodi
buchholz
et
al
major
immunodomin
epitop
protein
lie
amino
acid
lu
et
al
memori
b
cell
could
isol
convalesc
sar
patient
immort
epsteinbarr
viru
gener
human
monoclon
antibodi
suffici
affin
protect
sar
infect
traggiai
et
al
antibodi
could
protect
mice
viral
replic
lung
nasal
viru
challeng
random
placebocontrol
trial
evalu
passiv
postexposur
prophylaxi
atrisk
group
undertaken
howev
retrospect
analysi
outcom
limit
number
sar
patient
continu
deterior
receiv
plasma
therapi
suggest
passiv
immun
may
shorten
hospit
stay
without
obviou
advers
effect
patient
soo
et
al
cheng
et
al
current
hyperimmun
globulin
produc
plasma
convalesc
patient
equin
plasma
produc
immun
inactiv
sarscov
avail
prophylact
trial
human
lu
et
al
zhang
et
al
human
monoclon
produc
singlechain
variabl
region
fragment
domain
two
nonimmun
human
antibodi
librari
also
produc
sui
et
al
one
singlechain
variabl
region
fragment
block
receptor
interact
bind
domain
passiv
immun
ferret
hamster
mice
human
mab
effect
suppress
viral
replic
lung
ter
meulen
et
al
traggiai
et
al
robert
et
al
recent
potent
crossreact
monoclon
antibodi
highli
conserv
site
within
protein
neutral
zoonot
epidem
sarscov
report
et
al
zhu
et
al
broadli
crossreact
neutral
antibodi
may
use
treatment
option
role
antibodi
antibodydepend
enhanc
ade
sar
vaccin
controversi
extens
debat
perlman
dandekar
chen
subbarao
howev
evid
taken
limit
data
vitro
anim
experi
interpret
find
regard
implic
human
diseas
clear
concern
safeti
sar
vaccin
came
previou
anim
studi
ade
observ
domest
cat
vaccin
felin
infecti
periton
coronaviru
fipv
vennema
et
al
moreov
ferret
immun
mva
vaccin
express
protein
suffer
hepat
whilst
fail
develop
protect
weingartl
et
al
addit
variant
sarscov
resist
antibodi
neutral
infect
enhanc
antibodi
differ
variant
yang
et
al
vitro
condit
entri
human
bcell
line
sarscov
viru
could
carri
fcgriidepend
fashion
indic
ade
viru
entri
altern
cell
entri
mechan
sarscov
kam
et
al
howev
direct
evid
patient
sar
previou
exposur
relat
viru
likewis
evid
enhanc
diseas
lung
anim
infect
sarscov
follow
passiv
transfer
antibodi
sarscov
induc
infect
immun
also
macrophag
product
infect
sarscov
bisht
et
al
stadler
et
al
yang
et
al
greenough
et
al
kam
et
al
henc
potenti
ade
follow
sar
vaccin
low
howev
due
lack
anim
model
mimic
clinic
diseas
human
care
must
taken
interpret
safeti
data
sar
vaccin
sar
infect
begin
mucos
surfac
respiratori
system
viru
infect
lung
epitheli
cell
via
surfac
protein
effect
sar
vaccin
requir
elicit
neutral
antibodi
abolish
bind
viru
surfac
host
target
cell
andor
elimin
viru
earli
stage
infect
hope
activ
immun
sar
vaccin
stem
find
natur
human
infect
sarscov
lead
longliv
neutral
antibodi
respons
immun
sera
capabl
crossneutr
pseudotyp
virus
bear
protein
divers
highli
relat
human
sarscov
isol
nie
et
al
addit
longliv
memori
lymphocyt
differ
sarscov
structur
protein
present
peripher
blood
convalesc
sar
patient
li
et
al
peng
et
al
fan
et
al
numer
immun
strategi
variou
vaccin
express
vector
rout
immun
adjuv
use
develop
sar
vaccin
review
chen
subbarao
robert
et
al
viral
vector
express
target
gene
eukaryot
cell
codon
optim
immunogen
improv
use
immunostimulatori
sequenc
encod
intern
ribosom
entri
side
ire
among
structur
protein
potenti
vaccin
target
protein
protein
could
induc
neutral
antibodi
protect
anim
challeng
infect
regardless
method
antigen
deliveri
callendret
et
al
yang
et
al
kobing
et
al
see
et
al
bukreyev
et
al
hu
et
al
du
et
al
protein
protect
hamster
challeng
express
attenu
parainfluenza
type
vector
buchholz
et
al
mucos
immun
african
green
monkey
parainfluenza
type
protein
chimer
viru
elicit
neutral
antibodi
protect
viral
replic
upper
lower
respiratori
tract
challeng
live
sarscov
proteinencod
dna
vaccin
modifi
vaccinia
ankara
mva
express
protein
stimul
neutral
antibodi
product
provid
protect
live
viru
challeng
mice
yang
et
al
protect
mechan
mediat
antibodi
cell
taken
togeth
neutral
antibodi
bcell
respons
tcell
respons
protein
domin
patient
recov
sar
suggest
proteinbas
vaccin
may
suffici
induc
protect
immun
prophylact
vaccin
moreov
good
correl
neutral
antibodi
tcell
respons
li
et
al
human
two
independ
phase
clinic
trial
sar
vaccin
publish
inactiv
sarscov
vaccin
administ
via
two
intramuscular
immun
report
well
toler
immunogen
healthi
adult
volunt
china
lin
et
al
subject
seroconvert
day
postvaccin
geometr
mean
titer
neutral
antibodi
peak
two
week
second
vaccin
decreas
four
week
later
separ
dna
vaccin
trial
antigen
use
target
subject
seroconvert
receiv
immun
martin
et
al
neutral
antibodi
respons
peak
week
subject
remain
posit
week
postvaccin
addit
dna
vaccin
induc
spikespecif
tlymphocyt
respons
subject
week
postvaccin
spikespecif
tcell
respons
mainli
peak
tcell
respons
occur
week
maintain
throughout
trial
period
follow
initi
outbreak
sar
occur
hospitalbas
cluster
viru
rapidli
isol
sequenc
character
result
intern
public
health
effort
knowledg
quickli
transform
diagnost
reagent
tool
control
commun
outbreak
sar
infect
despit
wealth
activ
scientif
research
inform
mechan
viral
clearanc
immun
correl
protect
immunopathogenesi
sar
infect
remain
unclear
risk
sarscov
human
still
high
due
larg
number
anim
reservoir
sarscovlik
coronavirus
genom
instabl
rna
coronavirus
current
avail
anim
model
inadequ
develop
model
mimic
clinic
symptom
human
sar
infect
urgent
requir
mechanist
studi
vaccin
evalu
serial
analysi
acut
sar
sampl
analyz
innat
antibodi
tcell
respons
would
use
develop
treatment
strategi
prophylact
sar
vaccin
